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Mucosalmelanoma is a rare disease, which differs from its cutaneous counterpart genetically and for its clinical behaviour.Moreover
this is a heterogeneous disease based on the tissue of origin. As CT7 and CT10 are highly expressed in cutaneous melanoma and
are immunogenic in this disease, we analysed their expression throughout the different subtypes of mucosal melanoma and tumor
development.We detected a frequent expression of CT7 in primaries and correspondingmetastases (55%) as well as for CT10 (30%).
This expression resulted to be heterogeneous in the same tumor specimen and moreover influenced by the tissue of origin. Our
results support the role of these antigens in immunotherapy for mucosal melanoma.
1. Introduction
Cancer-testis (CT) antigen (Ags) represent a family of pro-
teins widely studied in the field of cancer immunother-
apy because of their restrictive expression pattern and
immunogenicity in cancer patients [1]. In normal tissues,
the expression of CT antigen is restricted to germ line
tissues (namely, placenta, ovaries, and testis), which express
small amounts of HLA molecules, making CT antigen no
more recognisable from the immune system. For this reason,
CTAgs represent ideal candidates for vaccination strategies
in cancer. Although expressed in several cancers, their role
in tumorigenesis is however unclear. Of interest is that the
aberrant expression of germ line genes in cancer reflects
the activation of a program which is silenced in somatic
cells; moreover, it is very well known that the gain of genes
is one of the driving forces of tumorigenesis [2]. This has
been also postulated for different CT antigen, expressed
diffusely in malignant tissues and frequently coexpressed as
the consequence of a commonpromoter demethylation [3, 4].
Among the CT antigen, the MAGE family is one of the most
extensively investigated antigen so far, with documented
expression in several cancers [2]. Between these, MAGE-
C1/CT7 (from now on CT7) andMAGE-C2/CT10 (from now
onCT10) are highly expressed in cutaneousmelanoma (CM),
represent strong prognostic markers [5], and spontaneously
induce a specific cellular immune response in melanoma
patients [6, 7].
Different from the cutaneous counterpart are mucosal
melanomas (MM). These are unrelated to ultraviolet light
exposure, develop at later age and more frequently at
advanced stage, are characterised by a high risk of local recur-
rence, and developmore often distantmetastases. Genetically
they differ from the cutaneous counterpart for the rare
presence of Braf mutations. Of interest is also that MM are
a heterogeneous disease and, based on the tissue of origin,
genetic differences have been detected as for c-kit mutations,
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which were found in almost half of genital melanoma and
nonsinonasal melanoma [8–10].
Due to clinical and genetic differences between CM and
MM and heterogeneity of MM, we aimed at evaluating the
expression of CT7 and CT10 in MM and their presence
throughout the different subtypes and tumor development.
2. Materials and Methods
2.1. Patients’ Population. 54 melanoma samples from 33
patients were analysed. From these, 33 out of 54 were pri-
mary melanomas of which 12 derived from a gynaecological
localization (vulva and vagina), 1 from the anus, 3 from the
conjunctiva, and 17 from the sinonasal region (of these, 3
cases were melanoma in situ). From 21/33 patients matching
samples were available as follows: primary andmetachronous
recurrence in 14 cases (8 local and 6 distant) and 7 cases with
primary and synchronous lymphonodal metastases. Descrip-
tion of samples and matching recurrence or metastases is
reported in Table S1 (see Table S1 in the SupplementaryMate-
rial available online at http://dx.doi.org/10.1155/2015/432479).
Tumor specimens were retrieved from the archives of the
Institute for Surgical Pathology Zurich (University Hospital
Zurich) and the Department of Dermatology of the Uni-
versity Umberto I, Rome, Italy, between 1996 and 2012. All
cases were reviewed from an experienced pathologist (DM).
Approval for the use of melanoma tissue was obtained from
the official ethical authorities of the Canton Zurich (StV 16-
2007, Amendment, 2014). All patients provided a written
informed consent in accordance with the Declaration of
Helsinki.
2.2. Immunohistochemistry. Tissue sections of 2.0 𝜇m were
cut, mounted on glass slides, deparaffinised, rehydrated, and
stained with hematoxylin-eosin using standard histological
techniques. Heavily pigmented melanomas are difficult for
immunohistochemical interpretation; therefore, in order to
avoid false positive results the slides were bleached before
using immunohistochemistry as previously described [11].
For immunohistochemical staining, the Ventana Bench-
mark automated staining system and Ventana reagents were
used (Ventana Medical Systems, Tucson, AZ). Immuno-
histochemistry was performed as recently described [12,
13]. Primary antibodies against CT7 (clone CT7-33, Dako
Cytomation, Dilution 1 : 80, Glostrup, Denmark) and CT10
clone LX-CT10.5, Dilution 1 : 100 [14] were used. Immunohis-
tochemical analysis for CT7 and CT10 was evaluated based
on the percentage of positive cells and defined as positive if
at least 5% of tumor cells were positive for each of the two
antigen [15, 16].
2.3. c-Kit Mutation Analysis. From 28 melanomas deriving
from 19 patients c-KITmutational analysis was known.These
data are available from our previous study [10].
2.4. Statistical Analysis. Correlations between primary
melanomas and their metastases for CT10 or CT7 expression
were analyzed using Spearman’s rank correlation. CT7
and CT10 expression were compared between different
localisation groups using the Mann-Whitney 𝑈 test.
𝑃 values below 0.05 were considered as significant. IBM
SPSS Statistics 20 (SPSS Inc., Chicago, IL) was used for
statistical analyses. GraphPad Prism 5 was used for Boxplots
and Graphs.
3. Results
3.1. MAGE-C1/CT7 and MAGE-C2/CT10 Expression in
Mucosal Melanoma. As previously described [5], we
found CT7 expression in the nucleus, cytoplasm, or both
compartments in both primary melanoma and metastases in
30 out of 54 (55%) melanoma lesions (Figure 1(a)).There was
a significant difference of CT7 expression between sinonasal
and gynecological melanoma (𝑃 = 0.002). Twenty-five out
of 32 (78%) sinonasal melanomas stained positive for CT7 in
contrast to only 3 out of 17 (18%) of gynecological melanoma
samples (Figure 1(b)). CT7 expression was also detected in 1
out of 2 anal melanoma lesions and 1 out of 3 melanomas of
the conjunctiva (Table S1(a)).
CT10 expression was detected in 16 of 54 melanomas
(30%); of these 13 showed a nuclear staining and 3 a combined
nuclear and cytoplasmic expression. In contrast to CT7, we
found no significant difference in CT10 expression between
sinonasal (30%) and gynecological (26%) melanoma (for
details, see Table S1(b)). CT10 expression was also detected
in 2 out of 2 anal melanoma lesions and none from the
conjunctiva (Table S1(b)).
Coexpression of CT7 and CT10 was detected in 6 out of
33 (18%) primaries and 5 out of 21 (24%) metastases (Figures
1(d) and 1(f)).
3.2. Correlation of MAGE-C1/CT7 and MAGE-C2/CT10
Expression in Primary Melanoma and Its Recurrence. Anal-
ysis of primary tumors and corresponding recurrence (21
cases) showed a significant correlation of CT7 expression in
primary MM and the recurrence (𝑃 = 0.001; Spearman’s
correlation coefficient 0,7) as well as of CT10 (𝑃 = 0.01;
Spearman’s correlation coefficient 0,6).
Analysing the matched samples of sinonasal melanomas
in detail, only one patient showed CT7 expression in the
primary tumor and negative recurrence. In all other patients,
if CT7 expression was present in the primary tumor, this was
also detected in the recurrence; moreover in five cases an
increase of CT7 expression was detected in the recurrence
(Figures 1(a), 1(c), and 1(e)). For CT10, 2 patients showed
an increased expression in the recurrence, 2 showed a stable
expression, and 3 cases, positive in the primary lesion, had
negative recurrences (Figures 2(a) and 2(b)).
4. Discussion
Mucosal melanoma is a rare disease with aggressive features
and, due to occult localization, the diagnosis most frequently
occurs in the late stages. This disease differs from the
cutaneous counterparts for its biology and genetic features
as is the case of BRAF, which is often mutated in cutaneous
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Figure 1: CT7 andCT10 expression inmelanoma: primary sinonasalmelanomawith positivity for CT7 in the in situ (arrow) and invasive part
(arrow head (a)). Maintained CT7 expression in the corresponding metastases (c) and local recurrence (e). Negativity for CT7 in a vaginal
melanoma (b). Nuclear positivity for CT10 (d) and cytoplasmic positivity for CT7 (f) on the same anal melanoma.
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Figure 2: Percentage of CT7 (a) and CT10 (b) melanoma cells in the primary melanoma and corresponding recurrence.
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melanoma and rarely in MM [8, 17]. Moreover, MM does not
represent a unique tumor entity but differs due to alternative
ontogenesis [8, 18] as, for example, mutations ofKIT aremore
often detected in gynecological MM rather than sinonasal
differing also clinically in distinct forms, a unilocular and
multilocular subtype [19]. Moreover, from a clinical perspec-
tive, a major event in MM compared to CM is also the more
frequent local recurrences due to the anatomical challenges
of a radical resection. For these reasons we focused our
interest in MM in order to evaluate the immunogenicity of
this rare disease. Indeed, immunotherapy plays a major role
in melanoma [20] with extraordinary responses in patients
treated with immune checkpoint inhibitors and we have
previously demonstrated the spontaneous immunogenicity
of cutaneous melanoma by the frequent expression on CT7
and CT10 and spontaneous immune responses to CT7 in
these patients. In this study, we analysed the expression of
CT7 and CT10 in 54 MM samples and detected a frequent
expression ofCT7 in primaries and correspondingmetastases
(55%) as well as of CT10 (30%). This expression resulted to
be heterogeneous in the same tumor specimen. This result is
very intriguing, because although heterogeneity ofmelanoma
is very well known,MAGE antigen are commonly considered
to be coexpressed upon activation of a common promoter
[21], especially for CT7 and CT10, which are located next to
each other on the X chromosome and share more than 50%
of sequence-homology.
This result suggests a possible modulation mechanism by
which tumors can escape the immune recognition by switch-
on and -off of protein thatmight also be involved in tumorige-
nesis and formation of metastases [12, 22–25]. Of importance
is that CT7 expression, compared to other vaccine-targets for
melanoma [26], does not get lost during tumor progression,
stressing the potential role of this antigen for therapeutic
purposes and monitoring of immune responses at all stages
of disease. To this, we have previously demonstrated and
characterized a CT7-specific cellular immune response in
melanoma patients [7]. One of these patients was affected by
sinonasal melanoma and his tumor sample is included in the
current cohort of cases, demonstrating the immunogenicity
of CT7 also in mucosal melanoma.
Of interest is that CT7might represent an ideal candidate
for vaccination especially in sinonasal melanomas, as its
expression, compared to the gynecological ones, occurs in
about 78% of samples compared to the gynecological ones,
where its expression is detected in 18% of lesions. This is of
major interest as our study demonstrates that CT7 expression
is influenced by the tissue of origin and might be modulated
by events related to ontogenesis.
In order to get new insights on the mechanism of expres-
sion of these genes we intended to define the correlation
between CT7 and CT10 expression and the presence of
activating KIT mutations; this is based on the frequent
activation of the KIT gene in MM and the finding that an
activated KIT may allow MAGE gene expression in mast cell
leukemia [27]. In contrast to mast cell leukemia we found
no clear-cut correlation between KIT mutation and MAGE
gene expression: mutational analysis for KIT was found in
5/28 available samples and CT7 expression was detected in
none and CT10 in 1 of 5 (20%) of these cases (primaries
and metastasis). However, due to the very limited number
of KIT activation positive cases, the relation between KIT
activation and CT7 and CT10 expression, respectively, in
mucosal melanoma is not yet clear and has to be analysed in
a larger cohort of patients.
Taken together our findings demonstrate CT7 and CT10
as good therapeutic targets for vaccination strategies and
monitoring of immune responses for patients with mucosal,
especially sinonasal, melanoma. However, as failure to cancer
vaccines due to tumor-associated immunosuppressionmight
occur, possible combinatorial treatments with immune-
checkpoint inhibitors would be ideal for future clinical
studies.
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